The Filing Desk

Heron Therapeutics vs Phathom Pharmaceuticals

Heron Therapeutics HRTX · Phathom Pharmaceuticals PHAT · Pharmaceuticals

Phathom Pharmaceuticals reported revenue of $175 million in fiscal 2025, about the same as Heron Therapeutics' $155 million in fiscal 2025. Heron Therapeutics' revenue grew 7.4% in its latest year, and Phathom Pharmaceuticals' grew 216.9%. Heron Therapeutics had an operating margin of -1.6%, against -91.4% at Phathom Pharmaceuticals. Free cash flow was −$28 million at Heron Therapeutics and −$167 million at Phathom Pharmaceuticals.

Side by side

Heron TherapeuticsPhathom Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$155M$175M
Revenue growth7.4%216.9%
Revenue growth a year, last 5 years11.8%—
Gross margin73.3%87.1%
Operating margin−1.6%−91.4%
Net margin−13.0%−126.3%
Free cash flow−$28M−$167M
Free cash flow margin−18.0%−95.4%
Return on capital−7.0%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count9.3%15.4%
Last close$0.26$5.08
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score4 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Heron TherapeuticsPhathom Pharmaceuticals
Operating margin
Percent of revenue
Heron TherapeuticsPhathom Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Heron TherapeuticsPhathom Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Heron Therapeutics and Phathom Pharmaceuticals pages.